Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM®;Dose Optimization and Enrollment ...
Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and ...
The company announced positive results from a clinical trial. In a phase 1/2 clinical trial for RTX-240 on patients with advanced solid tumors, the therapy showed encouraging safety and efficacy signs ...
CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday. Rubius said the ...
Shares of Rubius Therapeutics Inc. (NASDAQ:RUBY) soared by 85%, or $14.08, to trade midday at $30.51 on the word of first clinical, pharmacodynamic and tumor trafficking data from its ongoing phase ...
CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback